IMMU earnings call for the period ending December 31, 2018.
News & Analysis: Immunomedics
These stocks missed out on the market rally.
The FDA sent the biotech back to the drawing board.
A handful of updates heading into a critical regulatory review date had investors reconsidering a healthy market cap.
The company is inching closer to commercializing its first major product.
Find out which stock had the best news today.
It was off to the races earlier today following compelling data on Immunomedics' lead drug.
The release of upbeat clinical data from an important phase 2 trial causes traders to cheer.
Find out what sent these stocks so much lower.
A new CEO has the biotech's investors excited.